A 44-year-old woman in Warner Robins puts her phone on my exam table and shows me a photo of her ponytail from three years ago next to one taken last week. The diameter has visibly halved. She has been to two providers already. The first told her it was "just menopause" and recommended biotin. The second quoted her $14,000 for an FUE transplant and told her PRP "doesn't really work." She wants to know who is right.
The honest answer is that neither one is, because neither one did the workup. Hair loss is a presenting symptom that points to a category of mechanisms, not a single condition, and the treatment that works depends entirely on which mechanism is producing the loss. Surgical transplant and regenerative therapy are not competing products. They address different problems. Choosing between them without first identifying what the problem actually is is how patients waste years and thousands of dollars on treatments their physiology was never going to respond to.
I have spent the last several years building out the hair restoration program at this practice precisely because the standard approach to mid-life hair loss is so often inadequate. The version I run starts with a real workup.
The hair growth cycle and what disrupts it
A hair follicle cycles through three phases. Anagen is the active growth phase — 2 to 7 years, during which the follicle is producing a thick, pigmented hair shaft. Catagen is a brief 2 to 3 week transition. Telogen is the resting phase — about 3 months, during which the follicle is dormant and the existing hair is eventually shed. At any given moment in healthy scalp, roughly 85 to 90% of follicles are in anagen, 1 to 2% in catagen, and 10 to 15% in telogen.
Visible thinning happens when something disrupts that ratio. The disruption falls into a small number of recognizable patterns:
Telogen effluvium is a synchronized shift of follicles from anagen into telogen, producing diffuse shedding 2 to 4 months after the trigger. Triggers include severe illness, surgery, postpartum, significant weight loss, iron deficiency, thyroid dysfunction, certain medications, and major emotional stress. The follicle is intact. Once the trigger is removed, regrowth happens on its own over 6 to 12 months. Treatment is identifying and addressing the trigger.
Androgenetic alopecia is progressive miniaturization of follicles in genetically susceptible patterns — temporal recession and vertex thinning in men, central and frontal thinning with retained hairline in women. The mechanism is dihydrotestosterone (DHT) acting on follicles that express the androgen receptor, shortening the anagen phase and producing progressively thinner hair shafts each cycle until the follicle becomes vellus. The follicle is still alive but is producing finer and finer hair. This is the mechanism that responds best to regenerative work.
Cicatricial (scarring) alopecias are inflammatory or autoimmune destruction of the follicle itself. Once the follicle is destroyed, no regenerative or surgical treatment will recover it from that location. These conditions require dermatologic workup and treatment of the underlying inflammatory process before any regenerative work is appropriate.
Most patients I evaluate have some combination — a baseline of androgenetic miniaturization with a superimposed telogen effluvium episode driven by a specific trigger. Identifying both pieces matters because addressing one without the other produces a partial response and a frustrated patient.
How I evaluate a hair loss patient
The intake is detailed. I want to know the timing of onset, the pattern of loss (diffuse vs patterned, frontal vs vertex vs temporal), the family pattern, recent triggers, and the medication and supplement list. I look at the scalp directly under good lighting. I am looking at hair density across regions, hair shaft caliber, presence or absence of miniaturized hairs, scalp surface (any erythema, scaling, scarring, or pustules), and the pull test for active shedding.
Then I run the labs. The panel I order for hair loss includes ferritin (the single most important and most often missed lab — ferritin under 70 ng/mL is associated with shedding even with normal hemoglobin), full thyroid panel including TSH, free T3, free T4, and thyroid antibodies, vitamin D, B12, zinc, sex hormone panel including total and free testosterone, DHEA-S, and SHBG, fasting insulin and HbA1c, and an ANA screen if the pattern suggests an autoimmune component. For male patients I add DHT and a full PSA-relevant workup if oral DHT modulators are on the table.
The results often surprise patients. The woman from Warner Robins with the halved ponytail had a ferritin of 22, a TSH at 4.2 with positive thyroid antibodies, and a free testosterone in the bottom decile for her age. None of that had been checked by either prior provider. Treatment for her began with iron repletion and thyroid management before any regenerative work.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
What regenerative treatment actually does at the follicle level
When the workup identifies androgenetic miniaturization or a telogen-effluvium picture in a patient with viable follicles, regenerative treatment is the right tool. The mechanism is growth factor signaling delivered into the dermal compartment where the follicle stem cells reside.
DE|RIVE hair restoration is the protocol I use most frequently. It combines controlled-depth scalp microneedling with topical application of EXO|E exosome solution. The microneedling does two things — it creates micro-channels that allow the exosome solution to penetrate to the dermal papilla, and it triggers a controlled wound-healing response that activates dormant follicles via release of platelet-derived growth factor, vascular endothelial growth factor, and IGF-1. The exosomes themselves carry signaling molecules — microRNAs and growth factors derived from mesenchymal stem cell preparations — that promote anagen induction and prolongation.
The vampire facial PRP protocol adapted for the scalp is the patient-derived version. We draw blood, concentrate the platelets through centrifugation, and inject the platelet-rich plasma into the dermal compartment. The active components are the same family of growth factors, sourced from your own platelets rather than from an exogenous exosome preparation. Both approaches work. The choice between them depends on the patient's preference, the cost they want to commit to, and the specific clinical picture.
Surgical transplant — FUE or FUT — is a different intervention entirely. It moves follicles from a donor area (usually the occipital scalp, which is genetically resistant to androgenetic miniaturization) to the recipient area. It does not slow the underlying disease process; it relocates resistant follicles. For a patient with advanced patterned loss in a stable distribution and a good donor area, transplant produces durable density that regenerative work cannot match. For a patient with diffuse miniaturization, active telogen effluvium, or unresolved hormonal contributors, transplant alone is the wrong answer — the donor area may be limited, the recipient area is still under the same disease process, and the result will look thin again within a few years.
In my practice, the patients who do best with surgical transplant are the ones who first stabilized the underlying biology with regenerative work and hormonal optimization, then pursued transplant for the areas where regenerative work alone could not produce the density they wanted.
What I look for in a good regenerative candidate
A good DE|RIVE hair restoration candidate has miniaturizing but viable follicles (you can still see hair, even if it is fine), no active scarring or autoimmune destruction, addressable contributors on the lab panel, realistic expectations about timeline, and willingness to commit to the maintenance schedule. The patient who understands that this is a multi-year program and engages with it produces durable density. The patient who expects a one-and-done miracle is not a candidate I take on, because I know how that ends.
For mid-life patients, hormone therapy for women and men's hormone therapy for men are usually part of the parallel plan. Sex hormones modulate the growth cycle directly, and addressing the hormonal picture in parallel with regenerative work consistently outperforms doing one in isolation.
Realistic timeline and how I track progress
The hair growth cycle is what it is. Reduction in shedding shows up first, usually at 8 to 12 weeks. Visible density change takes 4 to 6 months because the new hairs have to grow long enough to contribute visible coverage. Full assessment of response takes 9 to 12 months. I take standardized photographs at baseline, at every reassessment, and at every maintenance visit, because subjective assessment of hair density is unreliable. Patients see their hair every day and adapt to it; the photographs are what tell us whether the protocol is working.
A typical initial course is 3 to 4 sessions at 4 to 6 week intervals, then maintenance at 4 to 6 month intervals. Stopping maintenance entirely usually produces gradual return to the prior trajectory over 6 to 12 months because the underlying biology has not changed.
Your concrete next step
If you have been weighing PRP, exosome therapy, or surgical transplant, do not commit to any of them without the workup. Book a 45-minute scalp consultation at the Columbus consultation office or in Warner Robins. Bring photographs from before the change started if you have them, your medication and supplement list, and any prior labs. The first visit covers the history, the scalp exam, and the lab order. The second visit, two to three weeks later, covers the lab review and the treatment plan. From that point we will know whether regenerative work is the right tool, whether transplant is on the table, and what the parallel plan needs to address.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.